Etoposide or alkylating agents should get complete blood counts (CBCs) yearly for evidence of myelodysplasia or a secondary leukemia.

依苷或者烷化剂治疗应该每年接受全细计数检查，以监测骨髓发育不良或继发性白发生迹象。